Ignite Creation Date:
2024-05-06 @ 6:56 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05836948
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-05-09
First Post:
2023-04-19
Brief Title:
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
Sponsor:
Shanghai Hengrui Pharmaceutical Co Ltd
Organization:
Shanghai Hengrui Pharmaceutical Co Ltd
Study Overview
Official Title:
An Open-label Phase I Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of SHR-9839 for Injection in Patients With Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an open-label phase I clinical trial of SHR-9839 in patients with advanced solid tumors The whole study is divided into three stages dose escalation dose expansion and efficacy expansion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None